Australian Doctor Who Had Pioneering Brain Tumour Treatment Dies/Image@ BBC
Richard Scolyer, a trailblazing Australian doctor renowned for his groundbreaking work in cancer research, has died at the age of 59, three years after being diagnosed with a highly aggressive brain tumor known as glioblastoma.
Scolyer gained international attention for opting to undergo a daring experimental treatment, a world-first procedure developed with his close associate, Professor Georgina Long.
Their collaborative research on advanced melanoma has transformed the prognosis for patients, turning what was once considered a terminal diagnosis into a manageable condition, ultimately saving countless lives.
In a heartfelt open letter announcing his passing, Scolyer expressed his desire to continue contributing to the field even during his most challenging moments.
”I write this letter as a final farewell to all those I have had the immense privilege of loving, sharing life’s adventures with, working alongside, and meeting during what can only be described as a life filled with joy, optimism, opportunity, and passion,” he stated.
Prime Minister Anthony Albanese praised Scolyer as “one of our brightest lights and one of our biggest hearts,” highlighting how he shared his journey with the public and inspired many along the way.
As one of Australia’s most esteemed medical professionals, Scolyer was recognized as a national treasure.
In 2024, he was honored as Australian of the Year alongside Long for their contributions to cancer treatment.
As co-directors of the Melanoma Institute Australia, Scolyer and Long’s research on immunotherapy has significantly improved outcomes for patients with advanced melanoma globally.
The survival rate has surged from less than 10% to nearly 50%, effectively curing many individuals.
Scolyer also took pride in mentoring aspiring pathologists throughout his career.
”I have always believed that we bear a responsibility to strive for a better future for others and leave the world improved… I have embraced that philosophy wholeheartedly,” he remarked.
Glioblastomas, which develop in the brain’s connective tissue, are notoriously difficult to treat.
The standard approach, surgical removal followed by radiation and chemotherapy, has seen little change over the past twenty years, with most patients surviving less than a year post-diagnosis.
”It didn’t feel right to accept an inevitable end without exploring alternatives,” Scolyer stated. “It’s an incurable cancer? Well, I refuse to accept that!”
Long shared his determination, spending time grieving before strategizing after learning about her friend’s diagnosis.
Her team discovered that immunotherapy is more effective when a combination of drugs is administered prior to surgery.
Consequently, in 2023, Scolyer became the first brain cancer patient to receive pre-surgery combination immunotherapy.
He also received a personalized vaccine tailored to the specific characteristics of his tumor, designed to enhance the cancer-fighting capabilities of the treatment.
Although they understood the odds of achieving a cure were slim, both Scolyer and Long hoped the experimental approach would extend his life.
Subsequent scans indicated a positive immune response in Scolyer’s brain, prompting a small clinical trial to attempt to replicate these encouraging results.
”This was science in action!” esteemed melanoma surgeon John Thompson AO remarked in tribute to his friend. Describing Scolyer as a “cheery, down-to-earth lad from Launceston” and an exceptional scientist, he added: “He will be remembered as a truly great Australian.”
In a statement on Monday, Albanese reflected on Scolyer’s journey: “Richard’s path was arduous and daunting, ‘My uncertain path,’ as he described it with characteristic humility.
Yet he navigated it with remarkable courage, determination, and grace. His willingness to share his experience was an act of profound generosity.”
Scolyer is survived by his wife, fellow pathologist Katie Nicholl, and their three children.
In his letter, he reflected on being “perhaps fortunate” that the physical and cognitive effects of his brain cancer likely shielded him from fully recognizing his decline during those final weeks.
”I write this knowing that my incredible family would have been by my side every moment, just as they have been throughout my cancer journey… They exemplify the very best of humanity and fill me with immense pride.”
Scolyer, who shared his treatment experience online, also expressed gratitude to Australians for their overwhelming support.
”You’ve laughed with me, wept with me, and offered encouragement and motivation when I needed it most.
I haven’t glossed over my journey, and I genuinely appreciate you allowing me the space and opportunity to share it with you, imperfections and all.”
He urged scientists to remain courageous and curious, and called on governments to invest in their innovations.
”We can and must continue to challenge limits to advance the field of oncology.”
By: Magdalene Agyeiwaa Sarpong